Coherus And Formycon’s Ranibizumab Rapidly Ramps Up In US
Cimerli Biosimilar To Lucentis Captures 38% Of Total Market Volume In December 2023
Formycon has reported positive uptake trends in the US for its Coherus-partnered ranibizumab biosimilar at the end of 2023, mirroring recent success in the UK with marketing ally Teva.
